Genetic Determinants in Hepatic Fibrosis: From Experimental Models to Fibrogenic Gene Signatures in Humans

Clinics in Liver Disease

Volumn 12, Issue 4, 2008, Pages 747-757

  Weber, Susanne ^a   Gressner, Olav A ^b   Hall, Rabea ^a   Grünhage, Frank ^a   Lammert, Frank ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cirrhosis; Fibrogenesis; Inbred mouse strains; Quantitative trait locus

Indexed keywords

ANGIOTENSIN; ANTIFIBROTIC AGENT; APOENZYME; CD14 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; GLUTATHIONE TRANSFERASE M1; GLYCOPROTEIN IB ALPHA; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; MANGANESE SUPEROXIDE DISMUTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR;

ALCOHOL ABUSE; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DISEASE COURSE; EXPERIMENTAL MODEL; GENDER; GENE MAPPING; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HEREDITY; HUMAN; LIFESTYLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHENOTYPE; QUANTITATIVE TRAIT LOCUS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; VIRUS HEPATITIS;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER CIRRHOSIS; MICE; MICE, INBRED STRAINS; POLYMORPHISM, GENETIC; QUANTITATIVE TRAIT LOCI;

EID: 54949138100     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.07.012     Document Type: Review

References (53)

1. Gressner A.M. The cell biology of liver fibrogenesis-an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 292 (1998) 447-452
2. Friedman S.L. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1 (2004) 98-105
3. Gressner A.M., and Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 10 (2006) 76-99
4. Schupan D., and Afdhal N.H. Liver cirrhosis. Lancet 371 (2008) 838-851
5. Bataller R., and Brenner D.A. Liver fibrosis. J Clin Invest 115 (2005) 209-218
6. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349 (1997) 825-832
7. Hillebrandt S., Goos C., Matern S., et al. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 123 (2002) 2041-2051
8. Lammert F. Genetic determinants of complex liver diseases: mouse models and quantitative trait locus analysis. In: Rodés J., Benhamou J.P., Blei A., et al. (Eds). Textbook of hepatology: from basic science to clinical practice (2007), Blackwell Publishing, Oxford (UK) 371-383
9. Browning J.D., Kumar K.S., Saboorian M.H., et al. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 99 (2004) 292-298
10. Neale M.C., and Cardon L.R. Methodology for genetic studies of twins and families Dordrecht (1992), Kluwer Academic Publishers
11. Perola M., Sammalisto S., Hiekkalinna T., et al. Combined genome scans for body stature in 6,602 European twins: evidence for common Caucasian loci. PLoS Genet 3 (2007) e97
12. Reed T., Page W.F., Viken R.J., et al. Genetic predisposition to organ-specific endpoints of alcoholism. Alcohol Clin Exp Res 20 (1996) 1528-1533
13. Korstanje R., and Paigen B. From QTL to gene: the harvest begins. Nat Genet 31 (2002) 235-236
14. Richardson M.M., Powell E.E., Barrie H.D., et al. A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J Med Genet 42 (2005) e45
15. Huang H., Shiffman M.L., Friedman S., et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 46 (2007) 297-306
16. Paigen K. A miracle enough: the power of mice. Nat Med 1 (1995) 215-220
17. Mouse Genome Sequencing Consortium. Initial sequencing and comparative analysis of the mouse genome. Nature 420 (2002) 520-562
18. Bogue M. Mouse phenome project: understanding human biology through mouse genetics and genomics. J Appl Physiol 95 (2003) 1335-1337
19. Shi Z., Wakil A.E., and Rockey D.C. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 94 (1997) 10663-10668
20. Hillebrandt S., Wasmuth H.E., Weiskirchen R., et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 37 (2005) 835-843
21. Iredale J.P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117 (2007) 539-548
22. Roskams T.A., Theise N.D., Balabaud C., et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 39 (2004) 1739-1745
23. Accatino L., Contreras A., Fernandez S., et al. The effect of complete biliary obstruction on bile flow and bile acid excretion: postcholestatic choleresis in the rat. J Lab Clin Med 93 (1979) 706-717
24. Chang M.L., Yeh C.T., Chang P.Y., et al. Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation. World J Gastroenterol 11 (2005) 4167-4172
25. Kornek M., Raskopf E., Guetgemann I., et al. Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. J Hepatol 45 (2006) 370-376
26. Weiler-Normann C., Herkel J., and Lohse A.W. Mouse models of liver fibrosis. Z Gastroenterol 45 (2007) 43-50
27. Muriel P., and Escobar Y. Kupffer cells are responsible for liver cirrhosis induced by carbon tetrachloride. J Appl Toxicol 23 (2003) 103-108
28. Yeh C.N., Maitra A., Lee K.F., et al. Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 25 (2004) 631-636
29. Darvasi A. Experimental strategies for the genetic dissection of complex traits in animal models. Nat Genet 18 (1998) 19-24
30. Flint J., Valdar W., Shifman S., et al. Strategies for mapping and cloning quantitative trait genes in rodents. Nat Rev Genet 6 (2005) 271-286
31. Peters L.L., Robledo R.F., Bult C.J., et al. The mouse as a model for human biology: a resource guide for complex trait analysis. Nat Rev Genet 8 (2007) 58-69
32. The Complex Trait Consortium. The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet 4 (2003) 911-916
33. Hillebrandt S., Matern S., and Lammert F. Mouse models for genetic dissection of polygenic gastrointestinal diseases. Eur J Clin Invest 33 (2003) 155-160
34. Manly K.F., Cudmore Jr. R.H., and Meer J.M. Map Manager QTX, cross-platform software for genetic mapping. Mamm Genome 12 (2001) 930-932
35. Broman K.W. Mapping expression in randomized rodent genomes. Nat Genet 37 (2005) 209-210
36. Lander E.S., and Botstein D. Mapping Mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics 121 (1989) 185-199
37. Lander E., and Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 11 (1995) 241-247
38. Churchill G.A., and Doerge R.W. Empirical threshold values for quantitative trait mapping. Genetics 138 (1994) 963-971
39. Hillebrandt S., Sauerbruch T., and Lammert F. Identification of multiple interacting quantitative trait loci (QTL) for hepatic fibrosis in mice. Gastroenterology 130 (2006) A427
40. Wasmuth H.E., Wiederholt T., Dahl E., et al. The chemokine CXCL9 (MIG) is a genetic modifier of liver fibrogenesis in chronic hepatitis C. Hepatology 44 (2006) 568A
41. Berres M.L., Rüland A., Moreno Zaldivar M., et al. The CC chemokine RANTES (CCL5) mediates liver fibrosis in mice and humans. Z Gastroenterol (2008) 46
42. Pletcher M.T., McClurg P., Batalov S., et al. Use of a dense single nucleotide polymorphism map for in silico mapping in the mouse. PLoS Biol 2 (2004) e393
43. Cervino A.C., Darvasi A., Fallahi M., et al. An integrated in silico gene mapping strategy in inbred mice. Genetics 175 (2007) 321-333
44. Grupe A., Germer S., Usuka J., et al. In silico mapping of complex disease-related traits in mice. Science 292 (2001) 1915-1918
45. Wasmuth H.E., Matern S., and Lammert F. From genotypes to haplotypes in hepatobiliary diseases: one plus one equals (sometimes) more than two. Hepatology 39 (2004) 604-607
46. Day C.P. Genetic studies to identify hepatic fibrosis genes and SNPs in human populations. Methods Mol Med 117 (2005) 315-331
47. The International HapMap Consortium. The International HapMap Project. Nature 426 (2003) 789-796
48. Wasmuth H.E., Lammert F., and Matern S. Genetische Risikofaktoren der Fibrogenese bei chronischen Lebererkrankungen. Med Klin 98 (2003) 754-762
49. Österreicher C.H., Stickel F., and Brenner D.A. Genomics of liver fibrosis and cirrhosis. Semin Liver Dis 27 (2007) 28-43
50. Gressner O.A., Weiskirchen R., and Gressner A.M. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 11 (2007) 1031-1051
51. Ellervik C., Birgens H., Tybjaerg-Hansen A., et al. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 46 (2007) 1071-1080
52. Hellerbrand C., and Wasmuth H.E. Genomewide genetic association studies in hepatology: the end of searching for the needle in the haystack?. Hepatology 46 (2007) 1661-1663
53. Kruglyak L. The road to genome-wide association studies. Nat Rev Genet 9 (2008) 314-318